Calcium channel subtypes for cholinergic and nonadrenergic noncholinergic neurotransmission in isolated guinea pig trachea.
The Ca(2+) channel subtypes in the neurotransmission of isolated guinea pig trachea were elucidated by monitoring the effects of specific Ca(2+) channel blockers on cholinergic contractions and nonadrenergic noncholinergic (NANC) relaxation elicited by electrical field stimulation (EFS). In isolated guinea pig trachea, cholinergic contractile responses to low- and high-frequency EFS were inhibited by the selective N-type calcium channel blocker, ω-conotoxin MVIIA. ω-Agatoxin IVA (a selective P-type blocker), ω-conotoxin MVIIC (a nonselective N-, Q-, and P-type blocker), and nifedipine (a selective L-type blocker) were ineffective, whereas Ni(2+) (a T- and R-type blocker) facilitated cholinergic contractions and produced a late contracture when its concentration exceeded 30 μM. The more the concentration of Ni(2+) increased, the greater the number of incidences and the late contracture areas which occurred. Late contracture did not seem to be due to the effects of acetylcholine, tachykinins, or other polypeptides, but disappeared in the absence of indomethacin. The NANC relaxant responses elicited by the low- and high-frequency EFS were inhibited by ω-conotoxin MVIIA or Ni(2+), but unaffected by ω-Agatoxin IVA, ω-conotoxin MVIIC, and nifedipine. In the absence of indomethacin, Ni(2+) did not alter the ω-conotoxin MVIIA (100 nM)-resistant component of cholinergic contraction, but significantly further inhibited that of NANC relaxation. These results suggest that in isolated guinea pig trachea, cholinergic contraction is regulated by N-type calcium channels which may mask T- and R-type calcium channels and may be co-modulated by both, while NANC relaxation is mainly and independently controlled by N-, T-, and R-type calcium channels.
Shih
Chung-Hung
CH
Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Hsu
Hsin-Te
HT
Wang
Kuo-Hsien
KH
Shih
Chih-Hsieh
CH
Ko
Wun-Chang
WC
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000502:physiology*; D020864:Calcium Channels, N-Type / Q000502:physiology; D020908:Calcium Channels, R-Type / Q000502:physiology; D020747:Calcium Channels, T-Type / Q000502:physiology; D018678:Cholinergic Agents / Q000494:pharmacology*; D004558:Electric Stimulation; D006168:Guinea Pigs; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D009543:Nifedipine / Q000494:pharmacology; D009435:Synaptic Transmission / Q000187:drug effects*; D014132:Trachea / Q000187:drug effects* / Q000502:physiology; D020867:omega-Agatoxin IVA / Q000494:pharmacology; D020866:omega-Conotoxin GVIA / Q000494:pharmacology; D020960:omega-Conotoxins / Q000494:pharmacology
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D020864:Calcium Channels, N-Type; D020908:Calcium Channels, R-Type; D020747:Calcium Channels, T-Type; D018678:Cholinergic Agents; D020867:omega-Agatoxin IVA; D020960:omega-Conotoxins; C075851:omega-conotoxin-MVIIC; D020866:omega-Conotoxin GVIA; D009543:Nifedipine; D000109:Acetylcholine
Curr Opin Neurobiol. 1992 Jun;2(3):247-53
1322749
Neuroscience. 1996 Feb;70(3):817-24
9045091
Am J Physiol Lung Cell Mol Physiol. 2008 Mar;294(3):L523-34
18203813
Nature. 1992 Feb 27;355(6363):827-9
1311418
J Physiol. 1987 Dec;394:149-72
2451016
J Neurosci. 1996 Jul 1;16(13):4155-61
8753877
Nature. 1997 Oct 23;389(6653):816-24
9349813
J Physiol. 1993 Jan;460:719-39
8487216
Br J Pharmacol. 1991 Jan;102(1):91-4
2043935
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1651-5
6103537
Regul Pept. 1985 Dec;13(1):1-19
2418471
Neuron. 1993 Aug;11(2):291-303
8394721
Naunyn Schmiedebergs Arch Pharmacol. 1988 Aug;338(2):107-13
2460772
Neuron. 1992 Jul;9(1):69-77
1352986
Neurogastroenterol Motil. 2003 Jun;15(3):299-306
12787339
Br J Pharmacol. 1990 Oct;101(2):437-47
2175236
Can J Physiol Pharmacol. 1986 Aug;64(8):1096-103
3098395
Proc Natl Acad Sci U S A. 1987 Jun;84(12):4327-31
2438698
FASEB J. 1991 Sep;5(12):2677-83
1655547
Annu Rev Biochem. 1994;63:823-67
7979255
J Pharmacol Exp Ther. 1995 Apr;273(1):248-56
7714772
Br J Pharmacol. 1993 Dec;110(4):1285-90
8306066
Biochem Soc Trans. 1993 May;21(2):395-401
8103003
Nature. 1993 Jun 3;363(6428):455-8
8389006
J Clin Endocrinol Metab. 2005 Apr;90(4):2192-7
15671094
Br J Pharmacol. 1990 Aug;100(4):663-4
2207492
Science. 1994 Apr 1;264(5155):107-11
7832825
Eur J Pharmacol. 1997 Feb 26;321(2):217-23
9063691
Br J Pharmacol. 1995 Sep;116(1):1595-8
8564224
Annu Rev Pharmacol Toxicol. 1992;32:399-421
1318672
Am J Physiol. 1973 May;224(5):1072-80
4144764
Br J Pharmacol. 1996 Jun;118(3):797-803
8762110
Clin Exp Pharmacol Physiol. 1989 Apr;16(4):333-9
2568204
Proc Natl Acad Sci U S A. 1984 Sep;81(18):5871-5
6091117
Neuropharmacology. 1993 Nov;32(11):1075-88
8107963
J Appl Physiol Respir Environ Exerc Physiol. 1981 Feb;50(2):374-82
6259102
Prostaglandins. 1987 May;33(5):651-61
3588974
Br J Pharmacol. 1997 Feb;120(3):393-8
9031741
Pflugers Arch. 1995 Apr;429(6):873-5
7603842
J Physiol. 1996 Aug 1;494 ( Pt 3):687-95
8865066
Eur J Pharmacol. 1994 Aug 11;261(1-2):79-84
8001657
Neuroscience. 1979;4(11):1539-59
390416
Br J Pharmacol. 1996 Sep;119(1):49-56
8872356
Mol Pharmacol. 1995 Feb;47(2):348-53
7870043
J Physiol. 1994 Nov 1;480 ( Pt 3):613-25
7869272
J Physiol. 1987 Feb;383:231-49
2443646
J Clin Invest. 1980 Feb;65(2):314-20
7356681
Physiol Rev. 1995 Apr;75(2):277-322
7724664
Science. 1992 May 1;256(5057):677-9
1350109
J Physiol. 1995 Jan 15;482 ( Pt 2):283-90
7714822
Life Sci. 1997;60(12):883-92
9061045
Br J Pharmacol. 1995 Sep;116(1):1577-82
8564221
J Physiol. 1993 Nov;471:25-40
7907144
Br J Pharmacol. 1999 Sep;128(1):262-8
10498861
Neuron. 1992 Jul;9(1):85-95
1321648
J Physiol. 1988 Jan;395:233-53
2457676
Eur J Pharmacol. 1993 Feb 9;231(2):197-202
7681004
Science. 1988 Jan 1;239(4835):57-61
2447647
Eur J Pharmacol. 1994 Jun 2;258(1-2):155-8
7925595